

**Amendments to the Claims:**

1. - 36 (Canceled)

37. (New) A method for selecting optimized glycosylated monoclonal antibodies, wherein said antibodies have less than 50% of G0F and G1F glycan structure on their Fcγ, comprising:

a) bringing into contact a CD16 expressing effector cells of the immune system, which may or may not be transformed, in a reaction medium in the presence of an antibody and the antigen for said antibody,

b) measuring the amount of at least one cytokine produced by the CD16 expressing cell, and

c) selecting antibodies for which the level of said cytokine produced is increased by more than 100% compared with the control in the absence of antibody or in the presence of a given antibody as a negative reference.

38. (New) A method for evaluating the effectiveness of a monoclonal or polyclonal antibody, comprising:

a) bringing CD16 receptor expressing effector cells, which may be transformed so as to express the CD16 receptor, into contact in a reaction medium with a monoclonal (MoAb) or polyclonal antibody and an antigen for said antibody, the antibody being activated by the antigen, and the antigen being different from the CD16, and

b) measuring the amount of at least one cytokine produced by the CD16 expressing cell, and

c) performing an ADCC assay, wherein the measurement of the amount of IL-2 is correlated with an ADCC (antibody-dependent cellular cytotoxicity)-type activity.